Pub. Date : 2015 Apr
PMID : 25757539
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |
| 2 | Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway activation may be related to imatinib resistance; however, no study has focused on whether signal conduction of this pathway will change after imatinib resistance. | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |
| 3 | Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway activation may be related to imatinib resistance; however, no study has focused on whether signal conduction of this pathway will change after imatinib resistance. | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |
| 4 | The activation of AKT/mTOR was significantly higher in imatinib secondary resistant GIST (53.1 %) than in imatinib-sensitive (27.1 %) and primary resistant GIST (33.3 %) (P = 0.049). | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |
| 5 | The activation of AKT/mTOR was significantly higher in imatinib secondary resistant GIST (53.1 %) than in imatinib-sensitive (27.1 %) and primary resistant GIST (33.3 %) (P = 0.049). | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |
| 6 | AKT/mTOR status was inactivated in pre-imatinib and on-treatment samples in eight patients with effective imatinib; however, the status of six patients was changed from inactivated to activated in 12 patients at the time of tumor progression. | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |
| 7 | AKT/mTOR status was inactivated in pre-imatinib and on-treatment samples in eight patients with effective imatinib; however, the status of six patients was changed from inactivated to activated in 12 patients at the time of tumor progression. | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |
| 8 | PI3K/AKT/mTOR pathway can be partly activated after imatinib secondary resistance in GIST. | Imatinib Mesylate | mechanistic target of rapamycin kinase | Homo sapiens |